Clinical Trials Browser

Withdrawn × INDUSTRY × Pemetrexed × Clear all

NCT06093503 2024-06-26

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02531854 2023-12-19

A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05791097 2023-07-24

AdvanTIG-306

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Phase 3 Withdrawn

Uterine Cervical Neoplasms

NCT03770299 2022-03-24

CheckMate 9TN

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04430933 2021-08-18

A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04611776 2021-06-16

CATHAYA

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04203511 2020-06-09

INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03920839 2020-04-24

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Phase 1 Withdrawn

Other solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung